Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Compugen Ltd (CGEN)

Compugen Ltd (CGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference PR Newswire - Thu Apr 9, 6:00AM CDT

HOLON, Israel , April 9, 2026 /PRNewswire/ --  Compugen Ltd.  (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced...

CGEN : 2.86 (+1.42%)
Compugen: Q4 Earnings Snapshot AP - Mon Mar 2, 6:17AM CST

Compugen: Q4 Earnings Snapshot

CGEN : 2.86 (+1.42%)
Compugen Reports Fourth Quarter and Full Year 2025 Results PR Newswire - Mon Mar 2, 6:00AM CST

HOLON, ISRAEL , March 2, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by...

CGEN : 2.86 (+1.42%)
Compugen to Participate in Upcoming Investor Conferences PR Newswire - Thu Feb 19, 6:00AM CST

HOLON, Israel , Feb. 19, 2026 /PRNewswire/ -- Compugen Ltd.  (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered...

CGEN : 2.86 (+1.42%)
Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026 PR Newswire - Tue Feb 17, 6:00AM CST

HOLON, Israel , Feb. 17, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered...

CGEN : 2.86 (+1.42%)
Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors PR Newswire - Thu Feb 12, 6:00AM CST

HOLON, Israel , Feb. 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered...

CGEN : 2.86 (+1.42%)
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million PR Newswire - Wed Dec 17, 2025

HOLON, Israel , Dec. 17, 2025 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery...

CGEN : 2.86 (+1.42%)
Compugen: Q3 Earnings Snapshot AP - Mon Nov 10, 2025

Compugen: Q3 Earnings Snapshot

CGEN : 2.86 (+1.42%)
Compugen Reports Third Quarter 2025 Results PR Newswire - Mon Nov 10, 2025

HOLON, Israel , Nov. 10, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery...

CGEN : 2.86 (+1.42%)
Compugen to Participate in Stifel 2025 Healthcare Conference PR Newswire - Tue Nov 4, 2025

HOLON, Israel , Nov. 4, 2025 /PRNewswire/ --  Compugen Ltd.  (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target...

CGEN : 2.86 (+1.42%)

Barchart Exclusives

Alphabet at $4 Trillion: Why the King of Tech Is Feeling Cramped on Planet Earth Barchart - 7 minutes ago
Alphabet has successfully defended its dominance, effectively becoming a proxy for the global economy. While its current valuation is sound, its huge scale now creates a growth ceiling tethered to global GDP, forcing a dilemma where future outperformance depends on inventing entirely new market paradigms. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.